AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01516879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
Study NCT01516879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
Study NCT01516879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Background lipid lowering therapy: ezetimibe 10 mg orally once a day
Study NCT01516879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Background lipid lowering therapy: ezetimibe 10 mg orally once a day
Study NCT01516879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Only
Description: Diet only, no lipid lowering background drug given
Study NCT01516879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet Only
Description: Diet only, no lipid lowering background drug given
Study NCT01072201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan and Fluoride
Description: Brush twice daily
Study NCT01072201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study NCT00647621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Phenytoin Sodium Capsules 100 mg
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Study NCT00647621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilantin® Kapseals® 100 mg
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Study NCT03641352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
Study NCT03641352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
Study NCT03989193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided alveolar ridge splitting technique
Description: The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm.
Study NCT04295603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toucher Massage (TM) on the feet
Description: The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
Study NCT04295603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homedics HM MP RELEX 90 device
Description: The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator.
Study NCT00584038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational instruction and phone follow-up
Description: Educational instruction and phone follow-up.
Study NCT00584038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational instruction in clinic
Description: Educational instruction in clinic.
Study NCT00220025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
Study NCT00678561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment once daily for 28 days
Study NCT03444909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toconaute
Description: Monitoring of 20 min withToconaute
Study NCT00678561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment twice daily for 28 days
Study NCT00678561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Topical treatment once daily for 28 days
Study NCT00678561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Topical treatment twice daily for 28 days
Study NCT00004031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV every 21 days
Study NCT00004031 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 IV every 21 days
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00004031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00004031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00004031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow ablation with stem cell support
Study NCT00004031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00004031 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01282216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: 1440 ELISA units, or 1 mL, IM
Study NCT03444909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrophysiological device (Micromed)
Description: Monitoring of 20 min with the cardiotocograph
Study NCT01282216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: 0.5 mL IM
Study NCT00437034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Given IV
Study NCT04143412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tritace (Ramipril 10 mg)
Description: Stratified randomized clinical trial
Study NCT02456922 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Harmony 1 Sensor
Description: Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
Study NCT02066012 — intervention group
Intervention type: OTHER
Intervention: dysmetabolic iron overload syndrome
Study NCT05036564 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse.
Study NCT05036564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse.
Study NCT00222937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lessac-Madsen Resonant Voice Therapy
Description: Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
Study NCT00222937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Casper-Based Confidential Flow Therapy
Description: Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
Study NCT01354015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRMS
Description: USE OF TEXT MESSAGING SYSTEM
Study NCT02352116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional face-to-face education
Description: Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
Study NCT02002494 — intervention group
Intervention type: OTHER
Intervention: Different positions
Description: Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
Study NCT03497559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Classical music
Study NCT03497559 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Music
Description: Classical music
Study NCT01916304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium new formulation
Description: Levothyroxine tablets
Study NCT03429491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Protein-free, LC n-3 PUFA-free juice based supplement
Study NCT03429491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein
Description: Leucine-enriched whey protein
Study NCT03429491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC n-3 PUFA
Description: LC n-3 PUFA
Study NCT02352116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care management
Description: Current standard of care at a major U.S. teaching hospital.
Study NCT02352116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care management
Description: Current standard of care at a major U.S. teaching hospital.
Study NCT03717038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
Study NCT03717038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
Study NCT02192944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
Study NCT02192944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
Study NCT04788914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Active bamboo charcoal± probiotics
Description: Active bamboo charcoal 2g, TID probiotics 0.8g
Study NCT02648191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCoach II Stim
Description: A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active.
Study NCT02648191 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroCoach II Stim
Description: A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive.
Study NCT02908529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination product of Atomoxetine and Oxybutynin
Description: Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
Study NCT02908529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 2 tablets
Description: Placebo 2 tablets 2 hours before sleep
Study NCT03750734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
Study NCT03750734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
Study NCT01042691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
Study NCT04426552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
Study NCT04426552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
Study NCT01243307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 (or placebo) followed by placebo (or CT327)
Description: During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.
Study NCT02376582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA
Description: DNA co-administered with protein at month 0, 1 and 6
Study NCT02376582 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA
Description: DNA co-administered with protein at month 0, 1 and 6
Study NCT02376582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: Protein co-administered with DNA at month 0,1 and 6
Study NCT02376582 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIDSVAX B/E
Description: Protein co-administered with DNA at month 0,1 and 6
Study NCT03338907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycarbon (5% CO2+ 95% O2)
Description: Oxycarbon will be administered by mechanical ventilation
Study NCT03338907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycarbon (5% CO2+ 95% O2)
Description: Oxycarbon will be administered by mechanical ventilation
Study NCT03277859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAA-TBI
Description: Yoga twice a week for 75 minutes for 8 weeks
Study NCT03277859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAA-TBI
Description: Yoga twice a week for 75 minutes for 8 weeks
Study NCT00771654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Subjects will receive Phentermine 37.5mg everyday for one year
Study NCT00771654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily for one year
Study NCT02495636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1401
Description: CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
Study NCT02495636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
Study NCT02511873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fycompa
Description: Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
Study NCT02511873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
Study NCT05588024 — intervention group
Intervention type: DEVICE
Intervention: Head Up CPR based bundle of care
Description: All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
Study NCT00753207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Study NCT00753207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Study NCT00753207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biomarker analysis
Study NCT00753207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00753207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Study NCT00753207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT02698358 — intervention group
Intervention type: DEVICE
Intervention: Epic stent (Boston Scientific)
Study NCT04042883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute normovolemic hemodilution
Description: 500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
Study NCT00869648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extension
Description: After anaesthesia induction the head is placed in extension
Study NCT00869648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral head position
Description: After anaesthesia induction the head is placed in neutral position